AI for Pharma & Healthcare 2025

ev3 Inc. received FDA clearance to Market EverCross 0.035 and NanoCross 0.014

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Philips, Masimo Extend Partnership to Sensor...

Philips and Masimo have gone on to renew their...

Renovo from China Raises $67M Series...

Ronovo Surgical from China has gone on to close...

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...
ev3 Inc., a global endovascular device company, announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0.035 and NanoCross 0.014 peripheral angioplasty balloon catheters. ev3 expects to begin full commercialization of the EverCross and NanoCross peripheral balloon catheters globally in January 2009.

ev3 Inc., a global endovascular device company, announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0.035 and NanoCross 0.014 peripheral angioplasty balloon catheters. ev3 expects to begin full commercialization of the EverCross and NanoCross peripheral balloon catheters globally in January 2009.

Robert Palmisano, ev3's president and chief executive officer commented, We are looking forward to launching the EverCross and NanoCross balloons this January. Based on our experience to date, we believe both balloons will enhance customer ease of use and offer significantly better margins than our current distributed product.

The EverCross and NanoCross peripheral balloon catheters are designed to offer improved overall performance in peripheral angioplasty procedures. Among several new features, both catheters offer innovative beveled tip profiles for best-in-class lesion entry and a broad range of sizes, including the only 200 mm length .035" balloon available worldwide.

Latest stories

Related stories

Philips, Masimo Extend Partnership to Sensor Technologies

Philips and Masimo have gone on to renew their...

Renovo from China Raises $67M Series D Funding by JJDC

Ronovo Surgical from China has gone on to close...

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »